Patents by Inventor Barrett Allan

Barrett Allan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11623956
    Abstract: The present disclosure relates to antibodies that bind human CD19 (“anti-human CD19 antibodies” or “anti-human CD19 antibodies”), compositions comprising such anti-human CD19 antibodies, and methods of using such anti-human CD19 antibodies.
    Type: Grant
    Filed: February 22, 2021
    Date of Patent: April 11, 2023
    Assignee: Eli Lilly and Company
    Inventors: Barrett Allan, Jeffrey Streetman Boyles, Alison Lee Sim Budelsky, Kira Vladimirovna Rubtsova, Guifeng Zhang, Songqing Na
  • Publication number: 20210269520
    Abstract: The present disclosure relates to antibodies that bind human CD19 (“anti-human CD19 antibodies” or “anti-human CD19 antibodies”), compositions comprising such anti-human CD19 antibodies, and methods of using such anti-human CD19 antibodies.
    Type: Application
    Filed: February 22, 2021
    Publication date: September 2, 2021
    Inventors: Barrett Allan, Jeffrey Streetman Boyles, Alison Lee Sim Budelsky, Kira Vladimirovna Rubtsova, Guifeng Zhang, Songqing Na
  • Publication number: 20190031748
    Abstract: The present invention relates to antibodies that bind to human CGRP, compositions and kits comprising such CGRP antibodies, and methods of using such CGRP antibodies for detection of human CGRP.
    Type: Application
    Filed: January 20, 2017
    Publication date: January 31, 2019
    Inventors: Xiyun CHAI, Barrett ALLAN
  • Publication number: 20180291093
    Abstract: Bispecific antibodies are provided that bind Calcitonin Gene Related Peptide (CGRP) and Interleukin-23 (IL-23) and are characterized as having high affinity and strong simultaneous neutralizing properties to both CGRP and IL-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including Inflammatory Bowel Disease, such as Crohn's Disease and Ulcerative Colitis, Psoriatic Arthritis (PsA) and ankylosing spondylitis (AS).
    Type: Application
    Filed: October 30, 2015
    Publication date: October 11, 2018
    Applicant: Eli Lilly and Company
    Inventors: Robert Jan Benschop, Rohn L Millican, JR., Barrett Allan, Catherine Brautigam Beidler
  • Patent number: 9951146
    Abstract: Bispecific antibodies are provided that bind CD20 and B-cell Activating Factor of the TNF Family (BAFF) and are characterized as having high affinity and strong simultaneous neutralizing properties to both CD20 and BAFF. The bispecific antibodies of the invention are useful for treating autoimmune diseases including Systemic Lupus Erythematosus, Lupus Nephritis, and primary Sjögren's Syndrome.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: April 24, 2018
    Assignee: Eli Lilly and Company
    Inventors: Barrett Allan, Kristine Kay Kikly, Derrick Ryan Witcher
  • Patent number: 9708402
    Abstract: Bispecific antibodies are provided that specifically bind B-cell Activating Factor of the TNF Family (BAFF) and Interleukin-17A (IL-17) and are characterized as having high affinity and strong neutralizing properties to both BAFF and IL-17. The bispecific antibodies of the invention are expected to be useful in treating Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriasis (Ps), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PA), primary Sjögren's Syndrome (pSS), or Multiple Myeloma (MM).
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: July 18, 2017
    Assignee: Eli Lilly and Company
    Inventors: Barrett Allan, Robert Jan Benschop, Jirong Lu
  • Publication number: 20170073403
    Abstract: The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.
    Type: Application
    Filed: November 2, 2016
    Publication date: March 16, 2017
    Applicant: Eli Lilly and Company
    Inventors: Barrett ALLAN, Robert Jan BENSCHOP, Mark Geoffrey CHAMBERS, Ryan James DARLING
  • Patent number: 9505838
    Abstract: The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: November 29, 2016
    Assignee: Eli Lilly and Company
    Inventors: Barrett Allan, Robert Jan Benschop, Mark Geoffrey Chambers, Ryan James Darling
  • Publication number: 20160289342
    Abstract: Bispecific antibodies are provided that bind CD20 and B-cell Activating Factor of the TNF Family (BAFF) and are characterized as having high affinity and strong simultaneous neutralizing properties to both CD20 and BAFF. The bispecific antibodies of the invention are useful for treating autoimmune diseases including Systemic Lupus Erythematosus, Lupus Nephritis, and primary Sjögren's Syndrome.
    Type: Application
    Filed: March 24, 2016
    Publication date: October 6, 2016
    Inventors: Barrett Allan, Kristine Kay Kikly, Derrick Ryan Witcher
  • Publication number: 20160251430
    Abstract: Bispecific antibodies are provided that specifically bind B-cell Activating Factor of the TNF Family (BAFF) and Interleukin-17A (IL-17) and are characterized as having high affinity and strong neutralizing properties to both BAFF and IL-17. The bispecific antibodies of the invention are expected to be useful in treating Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriasis (Ps), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PA), primary Sjögren's Syndrome (pSS), or Multiple Myeloma (MM).
    Type: Application
    Filed: May 18, 2016
    Publication date: September 1, 2016
    Applicant: Eli Lilly and Company
    Inventors: Barrett ALLAN, Robert Jan BENSCHOP, Jirong LU
  • Patent number: 9416182
    Abstract: Bispecific antibodies are provided that specifically bind both Tumor Necrosis Factor alpha (TNF?) and Interleukin-17 (IL-17). The bispecific antibodies of the invention are useful for treating various autoimmune diseases, including Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS).
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: August 16, 2016
    Assignee: Eli Lilly and Company
    Inventors: Barrett Allan, Andrew Lawrence Glasebrook, Jirong Lu, Ying Tang, Derrick Ryan Witcher, Donmienne Doen Mun Leung, Pia Pauliina Yachi, Andrew Charles Vendel
  • Patent number: 9359448
    Abstract: Bispecific antibodies are provided that specifically bind B-cell Activating Factor of the TNF Family (BAFF) and Interleukin-17A (IL-17) and are characterized as having high affinity and strong neutralizing properties to both BAFF and IL-17. The bispecific antibodies of the invention are expected to be useful in treating Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriasis (Ps), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PA), primary Sjögren's Syndrome (pSS), or Multiple Myeloma (MM).
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: June 7, 2016
    Assignee: Eli Lilly and Company
    Inventors: Barrett Allan, Robert Jan Benschop, Jirong Lu
  • Patent number: 9328173
    Abstract: Provided are multifunctional antibodies, and/or antigen-binding fragments, that bind to, and inhibit the activity of, both human epidermal growth factor receptor (EGFR) and MET, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by EGFR and MET.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: May 3, 2016
    Assignee: Eli Lilly and Company
    Inventors: Hector Aldaz, Barrett Allan, Ling Liu, Jirong Lu, Ying Tang, Sheng-Hung Rainbow Tschang, Pia Pauliina Yachi
  • Publication number: 20150259415
    Abstract: The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.
    Type: Application
    Filed: June 4, 2015
    Publication date: September 17, 2015
    Applicant: ELI LILLY AND COMPANY
    Inventors: Barrett ALLAN, Robert Jan BENSCHOP, Mark Geoffrey CHAMBERS, Ryan James DARLING
  • Patent number: 9073991
    Abstract: The present invention provides human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the human engineered calcitonin gene related peptide (CGRP) antibodies or antigen-binding fragment thereof for the treatment of osteoarthritis pain.
    Type: Grant
    Filed: June 7, 2011
    Date of Patent: July 7, 2015
    Assignee: Eli Lilly and Company
    Inventors: Barrett Allan, Robert Jan Benschop, Mark Geoffrey Chambers, Ryan James Darling
  • Publication number: 20150175708
    Abstract: Provided are multifunctional antibodies, and/or antigen-binding fragments, that bind to, and inhibit the activity of, both human epidermal growth factor receptor (EGFR) and MET, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by EGFR and MET.
    Type: Application
    Filed: December 17, 2014
    Publication date: June 25, 2015
    Inventors: Hector ALDAZ, Barrett ALLAN, Ling LIU, Jirong LU, Ying TANG, Sheng-Hung Rainbow TSCHANG, Pia Pauliina YACHI
  • Publication number: 20140255406
    Abstract: Bispecific antibodies are provided that specifically bind both Tumor Necrosis Factor alpha (TNF?) and Interleukin-17 (IL-17). The bispecific antibodies of the invention are useful for treating various autoimmune diseases, including Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Ankylosing Spondylitis (AS).
    Type: Application
    Filed: March 4, 2014
    Publication date: September 11, 2014
    Applicant: Eli Lilly and Company
    Inventors: Barrett Allan, Andrew Lawrence Glasebrook, Jirong Lu, Ying Tang, Derrick Ryan Witcher, Donmienne Doen Mun Leung, Pia Pauliina Yachi, Andrew Charles Vendel
  • Publication number: 20130280256
    Abstract: Bispecific antibodies are provided that specifically bind B-cell Activating Factor of the TNF Family (BAFF) and Interleukin-17A (IL-17) and are characterized as having high affinity and strong neutralizing properties to both BAFF and IL-17. The bispecific antibodies of the invention are expected to be useful in treating Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Psoriasis (Ps), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PA), primary Sjögren's Syndrome (pSS), or Multiple Myeloma (MM).
    Type: Application
    Filed: April 16, 2013
    Publication date: October 24, 2013
    Applicant: Eli Lilly and Company
    Inventors: Barrett Allan, Robert Jan Benschop, Jirong Lu
  • Patent number: 8530414
    Abstract: The present invention relates to antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9), or antigen-binding fragments thereof, compositions comprising such PCSK9 antibodies or antigen-binding fragments, and methods of using the same for the treatment of hyperlipidemia or hypercholesterolemia.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: September 10, 2013
    Assignee: Eli Lilly and Company
    Inventors: Julian Davies, Ryan James Darling, Barrett Allan
  • Publication number: 20130071405
    Abstract: The present invention relates to antibodies to proprotein convertase subtilisin/kexin type 9 (PCSK9), or antigen-binding fragments thereof, compositions comprising such PCSK9 antibodies or antigen-binding fragments, and methods of using the same for the treatment of hyperlipidemia or hypercholesterolemia.
    Type: Application
    Filed: September 12, 2012
    Publication date: March 21, 2013
    Applicant: ELI LILLY AND COMPANY
    Inventors: Julian Davies, Ryan James Darling, Barrett Allan